Mutational signatures in upper tract urothelial carcinoma define etiologically distinct subtypes with prognostic relevance
Xuesong LiiD, Huan LüiD, Bao GuaniD, Zhengzheng XuiD, Yue Xi ShiiD, Juan LiiD, Wenwen Kong, Jin LiuiD, Dong FangiD, Libo LiuiD, Qi SheniD, Yanqing GongiD, Shiming HeiD, Qun HeiD, Liqun ZhouiD, Weimin CiiD
Abstract
Parts of East Asia have a very high upper tract urothelial carcinoma (UTUC) prevalence, and an etiological link between the medicinal use of herbs containing aristolochic acid (AA) and UTUC has been established. The mutational signature of AA, which is characterized by a particular pattern of A:T to T:A transversions, can be detected by genome sequencing. Thus, integrating mutational signatures analysis with clinicopathological data may be a crucial step toward personalized treatment strategies for the disease. Therefore, we performed whole-genome sequencing (WGS) of 90 UTUC patients from China. Mutational signature analysis via nonnegative matrix factorization method defined three etiologically distinct subtypes with prognostic relevance: (i) AA, the typical AA mutational signature characterized by signature 22, had the highest tumor mutation burden, the best clinical outcomes; (ii) Age, an age-related group featured by signatures 1 and 5, had the lowest weighted genome instability index score, the worst clinical outcomes; and (iii) DSB, signature with deficiencies in DNA double strand break-repair featured by signatures 3, the intermediate clinical outcomes. Additionally, the distinct AA subtype was associated with AA exposure, the highest number of predicted neoantigens and heavier lymphocytes infiltrating. Thus, it may be good candidate for immune checkpoint blockade therapy. Notably, we showed AA-mutational signature was also identified in histologically \"normal\" urothelial cells. Thus, non-invasive urine test based on the AA-mutational signature could take advantage of this \"field effect\" to screen individuals at increased risk of recurrence due to exposure to herbal remedies containing the carcinogen AA. Collectively, the findings here may accelerate the development of novel prognostic markers and personalized therapeutic approaches for UTUC patients in China.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Non-invasive detection of upper tract urothelial carcinomas through the analysis of driver gene mutations and aneuploidy in urine
Simeon Springer, Chung-Hsin Chen, … Kathleen G. Dickman·bioRxiv·Oct 16, 2017
- Molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma
J. A. Nakauma-Gonzalez, M. Rijnders, … J. L. Boormans·bioRxiv·Mar 17, 2021
- Constrained hypermutation and absence of TERT promoter mutations in Lynch syndrome-associated urothelial cancer
Jussi Nikkola, Lauri Ryyppö, … Matti Annala·Cell ReportsPeer-reviewed·Oct 1, 2025
- PIK3CA Mutational Analysis in Formalin-Fixed, Paraffin-Embedded Archival Tissues of Urothelial Carcinoma of Urinary Bladder
Alcides Chaux, Julie S. Cohen, … George J. Netto·bioRxiv·Jun 16, 2015
- Adenomas from individuals with pathogenic biallelic variants in the MUTYH and NTHL1 genes demonstrate base excision repair tumour mutational signature profiles similar to colorectal cancers, expanding potential diagnostic and variant classification applications
Romy Walker, Jihoon Eric Joo, … Peter Georgeson·medRxiv·Aug 8, 2024
- The evolution of genomic, transcriptomic, and single-cell protein markers of metastatic upper tract urothelial carcinoma
K. Ohara, A. F. Rendeiro, … J. M. Mosquera·bioRxiv·Nov 16, 2021